참고문헌
- Lim YS, Kim WR. The global impact of hepatic fibrosis and endstage liver disease. Clin Liver Dis 2008;12:733-746, vii. https://doi.org/10.1016/j.cld.2008.07.007
- Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol 2014;60:643-653. https://doi.org/10.1016/j.jhep.2013.09.016
- Jepsen P, Vilstrup H, Andersen PK. The clinical course of cirrhosis: the importance of multistate models and competing risks analysis. Hepatology 2015;62:292-302. https://doi.org/10.1002/hep.27598
- Timoh T, Protano MA, Wagman G, Bloom M, Vittorio TJ. A perspective on cirrhotic cardiomyopathy. Transplant Proc 2011;43:1649-1653. https://doi.org/10.1016/j.transproceed.2011.01.188
-
Krag A, Wiest R, Albillos A, Gluud LL. The window hypothesis: haemodynamic and non-haemodynamic effects of
${\beta}$ -blockers improve survival of patients with cirrhosis during a window in the disease. Gut 2012;61:967-969. https://doi.org/10.1136/gutjnl-2011-301348 - Carvalheiro F, Rodrigues C, Adrego T, Viana J, Vieira H, Seco C, et al. Diastolic dysfunction in liver cirrhosis: prognostic predictor in liver transplantation? Transplant Proc 2016;48:128-131. https://doi.org/10.1016/j.transproceed.2016.01.010
- Ruiz-del-Arbol L, Serradilla R. Cirrhotic cardiomyopathy. World J Gastroenterol 2015;21:11502-11521. https://doi.org/10.3748/wjg.v21.i41.11502
- Fede G, Privitera G, Tomaselli T, Spadaro L, Purrello F. Cardiovascular dysfunction in patients with liver cirrhosis. Ann Gastroenterol 2015;28:31-40.
- Wiese S, Hove JD, Bendtsen F, Moller S. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol 2014;11:177-186. https://doi.org/10.1038/nrgastro.2013.210
- Falletta C, Fili D, Nugara C, Di Gesaro G, Mina C, Baravoglia CM, et al. Diastolic dysfunction diagnosed by tissue Doppler imaging in cirrhotic patients: prevalence and its possible relationship with clinical outcome. Eur J Intern Med 2015;26:830-834. https://doi.org/10.1016/j.ejim.2015.10.009
- Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107-133. https://doi.org/10.1016/j.echo.2008.11.023
- Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016;29:277-314. https://doi.org/10.1016/j.echo.2016.01.011
- Moller S, Wiese S, Halgreen H, Hove JD. Diastolic dysfunction in cirrhosis. Heart Fail Rev 2016;21:599-610. https://doi.org/10.1007/s10741-016-9552-9
- Moller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002;87:9-15. https://doi.org/10.1136/heart.87.1.9
- Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649. https://doi.org/10.1002/bjs.1800600817
- Karagiannakis DS, Vlachogiannakos J, Anastasiadis G, Vafiadis-Zouboulis I, Ladas SD. Diastolic cardiac dysfunction is a predictor of dismal prognosis in patients with liver cirrhosis. Hepatol Int 2014;8:588-594. https://doi.org/10.1007/s12072-014-9544-6
- Kwon JH, Jang JW, Kim YW, Lee SW, Nam SW, Jaegal D, et al. The usefulness of C-reactive protein and neutrophil-to-lymphocyte ratio for predicting the outcome in hospitalized patients with liver cirrhosis. BMC Gastroenterol 2015;15:146. https://doi.org/10.1186/s12876-015-0378-z
- Di Martino V, Coutris C, Cervoni JP, Dritsas S, Weil D, Richou C, et al. Prognostic value of C-reactive protein levels in patients with cirrhosis. Liver Transpl 2015;21:753-760. https://doi.org/10.1002/lt.24088
- Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998;27:28-34. https://doi.org/10.1002/hep.510270106
- Puthumana L, Chaudhry V, Thuluvath PJ. Prolonged QTc interval and its relationship to autonomic cardiovascular reflexes in patients with cirrhosis. J Hepatol 2001;35:733-738. https://doi.org/10.1016/S0168-8278(01)00217-3
- Bernardi M, Maggioli C, Dibra V, Zaccherini G. QT interval prolongation in liver cirrhosis: innocent bystander or serious threat? Expert Rev Gastroenterol Hepatol 2012;6:57-66. https://doi.org/10.1586/egh.11.86
- Henriksen JH, Gotze JP, Fuglsang S, Christensen E, Bendtsen F, Moller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003;52:1511-1517. https://doi.org/10.1136/gut.52.10.1511
- Pimenta J, Paulo C, Gomes A, Silva S, Rocha-Goncalves F, Bettencourt P. B-type natriuretic peptide is related to cardiac function and prognosis in hospitalized patients with decompensated cirrhosis. Liver Int 2010;30:1059-1066.
- Shi LY, Jin R, Lin CJ, Wu JS, Chen XW, Yu Z, et al. B-type natriuretic peptide and cirrhosis progression. Genet Mol Res 2015;14:5188-5196. https://doi.org/10.4238/2015.May.18.9
- Ha JW, Oh JK. Therapeutic strategies for diastolic dysfunction: a clinical perspective. J Cardiovasc Ultrasound 2009;17:86-95. https://doi.org/10.4250/jcu.2009.17.3.86
- Ruiz-del-Arbol L, Achecar L, Serradilla R, Rodriguez-Gandia MA, Rivero M, Garrido E, et al. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension, and a normal creatinine. Hepatology 2013;58:1732-1741. https://doi.org/10.1002/hep.26509
피인용 문헌
- Cirrhotic cardiomyopathy: An independent prognostic factor for cirrhotic patients vol.24, pp.4, 2018, https://doi.org/10.3350/cmh.2018.0098
- Syndecan-1: A Review on Its Role in Heart Failure and Chronic Liver Disease Patients’ Assessment vol.2019, pp.None, 2018, https://doi.org/10.1155/2019/4750580
- An update on cirrhotic cardiomyopathy vol.13, pp.5, 2019, https://doi.org/10.1080/17474124.2019.1587293
- Liver cirrhosis and left ventricle diastolic dysfunction: Systematic review vol.25, pp.32, 2019, https://doi.org/10.3748/wjg.v25.i32.4779
- Impact of the 2016 ASE/EACVI Guidelines on diastolic function reporting in routine clinical practice vol.37, pp.4, 2018, https://doi.org/10.1111/echo.14645
- Early echocardiographic signs of diastolic dysfunction predict acute kidney injury in cirrhotic patients vol.83, pp.11, 2018, https://doi.org/10.1097/jcma.0000000000000422
- Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications vol.18, pp.2, 2021, https://doi.org/10.1038/s41569-020-0433-5
- Diastolic Dysfunction Is a Predictor of Poor Survival in Patients with Decompensated Cirrhosis vol.2021, pp.None, 2018, https://doi.org/10.1155/2021/5592376
- The prevalence of cirrhotic cardiomyopathy according to different diagnostic criteria vol.41, pp.5, 2018, https://doi.org/10.1111/liv.14769
- Direct Bilirubin Is More Valuable than Total Bilirubin for Predicting Prognosis in Patients with Liver Cirrhosis vol.15, pp.4, 2018, https://doi.org/10.5009/gnl20171